Product image of Icatibant Aguettant (Icatibant) supplied by GNH India

Icatibant Aguettant

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Aguettant (Icatibant)

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH India supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across global markets.

Manufacturer / TM Owner

Laboratoire Aguettant

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to manage hereditary angioedema, a disorder characterized by bradykinin‑mediated swelling.

  • Acute hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during an attack.
  • Hereditary angioedema type I: reduces attack severity and duration.
  • Hereditary angioedema type II: alleviates symptoms by blocking bradykinin effects.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By blocking this receptor, it interrupts the pathway responsible for the rapid swelling seen in hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Injection site pain: discomfort at the site of subcutaneous administration.
  • Redness or swelling at injection site: localized inflammatory response.
  • Nausea: mild gastrointestinal upset.
  • Headache: transient cranial discomfort.
  • Dizziness: occasional light‑headedness.
  • Fatigue: feeling of tiredness after dosing.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
  • Severe injection site necrosis: tissue damage requiring medical attention.
  • Thrombocytopenia: low platelet count observed in rare cases.
  • Acute hypertension: sudden rise in blood pressure.
  • Pulmonary edema: fluid accumulation in lungs, very rare.
  • Cardiovascular collapse: severe drop in blood pressure and heart function.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown excretion in milk; weigh benefits against possible risks.
  • Renal impairment: monitor closely as the drug is primarily renally excreted.
  • Concomitant ACE inhibitors: may increase risk of angioedema; assess necessity.
  • Hypersensitivity: discontinue immediately if allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medications that affect the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: may potentiate bradykinin‑mediated angioedema.
  • Neprilysin inhibitors: increase bradykinin levels, raising risk of swelling.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing oral contraceptives: may elevate bradykinin activity.
  • Other B2 receptor antagonists: additive pharmacodynamic effects.
  • Drugs affecting renal clearance: may alter icatibant elimination.

Frequently Asked Questions

Icatibant Aguettant is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. It works by rapidly reducing swelling and associated symptoms during an episode.

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the swelling characteristic of hereditary angioedema.

The dosing regimen for icatibant is determined by the prescribing healthcare professional based on the patient’s condition, severity of the attack, and clinical guidelines. Patients should follow the prescriber’s instructions precisely.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas alternative therapies such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant offers a rapid, targeted approach to block bradykinin‑mediated swelling, while protein replacement works by restoring the missing inhibitor.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe injection‑site necrosis, and rare cardiovascular events like acute hypertension or pulmonary edema. Patients should be monitored for these events during and after administration.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled hypertension, or those taking ACE inhibitors without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT